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Background-—Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and
iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in
myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance.
Methods and Results-—Fifty-three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive
intravenous FCM or placebo in a multicenter, double-blind study. T2* and T1 mapping cardiac magnetic resonance sequences,
noninvasive surrogates of intramyocardial iron, were evaluated before and 7 and 30 days after randomization using linear mixed
regression analysis. Results are presented as least-square means with 95% CI. The primary end point was the change in T2* and T1
mapping at 7 and 30 days. Median age was 73 (65–78) years, with N-terminal pro-B-type natriuretic peptide, ferritin, and
transferrin saturation medians of 1690 pg/mL (1010–2828), 63 ng/mL (22–114), and 15.7% (11.0–19.2), respectively. Baseline
T2* and T1 mapping values did not significantly differ across treatment arms. On day 7, both T2* and T1 mapping (ms) were
significantly lower in the FCM arm (36.6 [34.6–38.7] versus 40 [38–42.1], P=0.025; 1061 [1051–1072] versus 1085 [1074–1095],
P=0.001, respectively). A similar reduction was found at 30 days for T2* (36.3 [34.1–38.5] versus 41.1 [38.9–43.4], P=0.003), but
not for T1 mapping (1075 [1065–1085] versus 1079 [1069–1089], P=0.577).
Conclusions-—In patients with heart failure and iron deficiency, FCM administration was associated with changes in the T2* and T1
mapping cardiac magnetic resonance sequences, indicative of myocardial iron repletion.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT03398681. ( J Am Heart Assoc. 2020;9:
e014254. DOI: 10.1161/JAHA.119.014254.)
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I ron deficiency (ID) is common in patients with heart failure(HF).1 It is associated with reduced functional capacity,
quality of life, and increased risk of clinical events.1–4 In
patients with HF and ID (HF-ID), with or without anemia, iron
treatment with intravenous ferric carboxymaltose (FCM) has
consistently been shown to improve symptoms, functional
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capacity, and quality of life with an acceptable safety profile.5–8
The mechanisms whereby exogenous iron repletion leads to
clinical improvement in HF-ID are not completely understood.
Experimental studies have shown that iron depletion
impairs mitochondrial function and adenosine triphosphate
(ATP) synthesis affecting systolic and diastolic properties of
cardiomyocytes, and that all these deleterious effects are
reversed with iron treatment.9–12 In humans, some studies
have also shown that myocardial iron content is decreased in
patients with advanced HF13 and this is associated with
abnormal myocardial mitochondrial function.14 However, in
the clinical setting, the myocardial effects of intravenous iron
repletion in patients with HF-ID are largely unknown.
A cardiac magnetic resonance (CMR) sequence, T2*, has
been shown to provide a noninvasive estimation of myocardial
iron overload15,16 and myocardial iron depletion.17 Native T1
mapping has also emerged as a potential alternative tool for the
assessment of myocardial iron content.18 In a recently
published proof-of-concept pilot study of 8 patients with HF-
ID, our group reported an association between intravenous
FCM administration and myocardial iron repletion estimated by
T2*CMR.19 To further confirm these findings, the present study
is a prospective multicenter, double-blind, randomized clinical
trial of noninvasive estimation of changes in myocardial iron
after administration of FCM or placebo in patients with HF-ID
using CMR T2* and T1 mapping sequences.
Methods
Overall Study Design
The data that support the findings of this study are available
from the corresponding author upon reasonable request. This
investigator-initiated, multicenter, double-blind, randomized
clinical trial was designed to evaluate the effect of intravenous
FCM versus placebo on myocardial iron repletion estimated by
T2* and T1 mapping CMR sequences in patients with HF-ID.
The trial was conducted in 5 academic centers in Spain.20 The
patients provided signed informed consent before being
randomized 1:1 to receive either FCM or placebo. Intramy-
ocardial iron was evaluated at 3 time points: before treatment,
and 7 and 30 days after treatment. At 30 days, patients
assigned to placebo received intravenous FCM if ID persisted.
The study design was already published.20
The investigation conforms to the principles outlined in the
Declaration of Helsinki and Good Clinical Practice of the
International Conference on Harmonization. The study proto-
col was approved by Agencia Espa~nola del Medicamento y
Productos sanitarios (AEMPS) and by Comite Etico de
Investigacion Clınica (CEIC) del Hospital Clınico Universitario
de Valencia. CMR studies were performed and analyzed by a
core lab at ERESA (Valencia). Laboratory parameters were
analyzed in local laboratories. This study is registered at
http://clinicaltrials.gov (NCT03398681).
Study Population
The study population included patients with stable chronic HF
(New York Heart Association [NYHA] II–III), left ventricular
ejection fraction (LVEF) <50%, and ID (serum ferritin
<100 lg/L [absolute ID] or 100–299 lg/L with transferrin
saturation [TSAT] <20% [functional ID]), and hemoglobin
<15 g/dL.21 The inclusion and exclusion criteria were pub-
lished previously20 and are reported in detail in Table S1.
Study Procedures
Screening and eligibility assessment (visit 0)
In this visit, after reviewing the inclusion/exclusion criteria, the
patients signed and dated the informed consent form. The
following information was recorded: (1) clinical and demographic
variables, including a complete medical history, vital signs, and a
complete physical examination; (2) ECG; (3) functional capacity
parameters, including NYHA functional class and 6-minute
walking test (6MWT); (4) quality of life parameters, including
Kansas City Cardiomyopathy Questionnaire (KCCQ); (5) labora-
tory data, including hematology parameters, serum electrolytes,
parameters evaluating iron status (ferritin and TSAT), creatinine,
urea, estimated glomerular filtration rate, and NT-proBNP
(N-terminal pro-B-type natriuretic peptide); (6) 2-dimensional
echocardiography; and (7) CMR parameters.
24-hour visit
At this visit, after clinical evaluation, the patients were
randomized to receive FCM or placebo. In addition, vital signs,
Clinical Perspective
What Is New?
• The exact mechanism explaining the benefits of treatment
with ferric carboxymaltose in patients with heart failure
remains not fully explained.
• This study shows that treatment with ferric carboxymaltose
resulted in significant short-term changes in cardiac mag-
netic resonance sequences that are consistent with
myocardial iron repletion.
What Are the Clinical Implications?
• This study opens a new line of research about the utility of
cardiac magnetic resonance for noninvasive quantification
of myocardial iron status, including not only iron overload,
but also iron deficiency and response to treatment
(myocardial iron repletion).
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complete physical examination, and functional class evalua-
tion (NYHA) were noted.
7- and 30-day visits
At these visits, the same explorations/variables were
recorded as at visit 0, except the ECG and echocardiography,
which were performed only at the 30-day visit. During the
study period, all concomitant medications and clinical adverse
events (death from all causes or hospitalization for acute HF)
were recorded. Optional visits were permitted at the discre-
tion of the physician in charge, at which the same information
was recorded as in the preplanned visits.
Cardiac magnetic resonance
CMR studies were performed by 2 experienced operators on a
1.5-Tesla MR scanner (Essenza y Avanto, Siemens, Erlangen,
Germany) using the spine and phased array 6-channel surface
coils. No contrast media were used. All images were obtained
with electrocardiographic gating and breath-holding. Cine
images were acquired at rest in short-axis views every 1 cm
with steady-state free precession imaging sequences (time
resolution: 37 ms; voxel size: 1.791.797 mm). The LVEF was
calculated by semiautomatic planimetry of endocardial and
epicardial borders in short-axis view cine images. Left
ventricle diameters and volumes were also determined.
For T2* analysis, a region of interest was chosen in the mid-
left ventricular septum. The mean signal intensities of the
regions of interest were measured in the series of increasing
echo time images to give an exponential decay curve. The
monoexponential decay model and nonlinear curve fitting
algorithm were used to fit the curve to obtain the T2*
measurement. T1 mapping was performed using Modified
Look-Locker Inversion Recovery sequences with motion correc-
tion (voxel size: 1.591.597 mm) in 3 short axes (basal, medial,
and apical). After T1 maps were generated, a region of interest
was chosen in the mid-left ventricular septum in the 3 short axes
and the average T1 values were calculated. The same protocol
was repeated at 7 and 30 days. The technical specifications of
the CMR sequences were described elsewhere.20 CMR opera-
tors were also blinded to treatment allocation.
Trial Intervention
Eligible patients were randomized to receive FCM or placebo.
All patients received the assigned treatment with no place for
crossover.
Intravenous FCM or placebo
FCM solution (Ferinject [FCM], Vifor Pharma, Glattbrugg,
Switzerland) was given as a 20-mL perfusion (equivalent to
1000 mg of iron) diluted in a sterile saline solution (0.9% wt/
vol NaCl) administered over at least 15 minutes after
completion of all baseline study-related assessments.
Because FCM is a dark-brown solution that is easily distin-
guishable from the saline placebo, study personnel respon-
sible for the preparation and administration of the study drug
were aware of the group assignments and, therefore, not
involved in any study assessments.
In the placebo group, normal saline (0.9% weight/volume
NaCl) was administered as per the instructions for active therapy.
To ensure that patients were unaware of the study drug, the
materials used in drug administration were covered with
aluminum foil and the injectionsite shielded fromthepatient view.
Concomitant drugs
Indications for other HF-related drugs in both treatment
groups were handled according to the current recommenda-
tions for clinical practice and included the administration of
angiotensin-converting enzyme inhibitors, angiotensin recep-
tor blockers, sacubitril/valsartan, b-blockers, mineralocorti-
coid receptor antagonists, digoxin, ivabradine, diuretics, and
nitrate agents. Per study protocol, changes in HF therapy
during the study period were discouraged.
End Points
Primary end point
The main end point was to noninvasively estimate changes in
myocardial iron content as measured by T2* and T1 mapping
CMR sequences 7 and 30 days after FCM or placebo
administration.
Secondary end points
The secondary end point was to correlate posttreatment
changes in myocardial iron content (T2* and T1 mapping) with
concomitant changes in surrogate markers of disease severity
(LVEF, functional capacity [6MWT and NYHA class], quality of
life [KCCQ], NT-proBNP, and blood markers related to iron
biology [ferritin and TSAT]).
Safety end points
A strict policy was implemented regarding close adverse
event surveillance to ensure early detection and appropriate
management. Based on previous studies,7,8 the surveillance
specifically focused on (1) general disorders and administra-
tion site conditions, (2) skin and subcutaneous tissue
disorders, (3) nervous system disorders, (4) gastrointestinal
disorders, (5) vascular disorders, (6) ear and labyrinth
disorders, (7) injury, poisoning, and procedural complications,
and (8) cardiac disorders.
Subgroup analyses
We also included as part of the analysis the effect of
treatment on changes in T2* and T1 among age (≤75 years
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versus >75 years), ischemic heart disease (0/1), and anemia
(0/1) categories.
Follow-Up
No patients were lost to follow-up. T2* and T1-mapping values
could not be accurately obtained in 3 and 2 patients,
respectively. Reasons for unavailability included rejection for
repeating the CMR test (n=1 patient) and technical issues in
image acquisition (n=2 patients). In these cases, T2* and T1
mapping values were imputed.
Statistical Analysis
All statistical comparisons were made under an intention-to-
treat principle. Continuous variables were presented as
median with interquartile range. Discrete data were expressed
as frequency and percentages. The v2 test or Wilcoxon rank-
sum were used as appropriate to compare baseline charac-
teristics among the 2 treatment groups.
The statistical comparisons for the primary efficacy end
point tested the null hypothesis of no differences in changes
in myocardial iron content as estimated by T2* and T1
mapping CMR in patients treated with intravenous FCM or
placebo at 30 days. The alternative hypothesis stated differ-
ences in either direction. Because of the availability of 2-time
points, the 7-day evaluation was considered a co-primary end
point.
A linear mixed regression model was used for the analysis
of the primary end point. All analyses included adjustments
for hospital center (as a cluster variable), the interaction
term treatment9visit (7 and 30-day), and the baseline
(pretreatment) value of the regressed outcome. The inclusion
of other covariates was based on clinical judgment or
randomization inequalities at baseline. To limit the potential
for increasing type I error rate, we focused strictly on
between-group (FMC versus placebo) comparison at 30 and
7 days, respectively.
A similar approach was used for the subgroup analyses
after stratifying for the prespecified variables (age [≤75 years
versus >75 years], ischemic heart disease [0/1], and anemia
[0/1]). Such linear mixed regression model included a 3-level
interaction (FCM treatment9visit9subgroup variable).
For analysis of the correlations between changes in either
T2* or T1 mapping and changes in LVEF, 6MWT, NYHA class,
KCCQ, NT-proBNP, ferritin, and TSAT, we used linear regres-
sion analysis. For this analysis, the stratification at 7 and
30 days was ignored under the assumption that these
correlations may remain the same throughout follow-up.
These correlation models included the interaction between
the treatment and the delta of the parameter evaluated. The
normality of residuals was checked.
As a prespecified analysis, no adjustment for multiple
comparisons was made in any of the analyses. Results from
linear mixed regression model and linear regression analysis are
presented as least-square means with 95% CIs and P values.
Missing values in T2* and T1 mapping were imputed using
a reference-based sensitivity analysis via multiple imputation
for longitudinal trials with protocol deviation.22 A 2-sided
P value of 0.05 was considered significant for all analyses. All
analyses were performed using Stata 15.1 (Stata Statistical
Software, College Station, TX). The multiple imputation




From May 2017 to June 2018, a total of 55 patients were
preselected for participation in this trial. Fifty-three patients
were finally randomized to receive FCM (n=27) or placebo
(n=26) (Figure 1).
The median age of the study population was 73 (interquar-
tile range 65–78) years, 75.5% were men, 52% had type 2
diabetes mellitus, 43.4% had prior ischemic heart disease,
60.4% had a prior admission for acute heart failure in the last
12 months, and most (94.3%) were in NYHA functional class
II. The median (interquartile range) CMR-LVEF, NT-proBNP,
and estimated glomerular filtration rate were 39% (33–45),
1690 pg/mL (1010–2828), and 60 (49.3–72.9) mL/min per
1.73 m2, respectively. All patients had ID at baseline, with 37
(69.8%) and 16 (30.2%) patients exhibiting absolute and
functional ID, respectively. The median (interquartile range)
values of ferritin and TSAT were 63 (33–114) lg/L and 15.7%
(11–19.2%), respectively. Anemia (WHO criteria) was present
in 16 (30.2%) patients. Baseline ferritin and TSAT did not
correlate with T2* (Spearman r=0.08, P=0.552 and Spear-
man r=0.199, P=0.153, respectively) or T1 mapping
(Spearman r=0.02, P=0.903 and Spearman r=0.173,
P=0.216, respectively). The baseline characteristics of
patients in the 2 treatment groups are given in Table 1. No
significant differences were found between the treatment
groups. Raw data (CMR parameters [T2*, T1-mapping, and
LVEF], KCCQ, and 6MWT at different visits [baseline, 7 and
30-day]) across treatment arms are presented in Table S2.
Primary End Point
Compared with placebo, both 7-day T2* and T1 mapping were
significantly lower in the FCM arm (36.6 ms [34.6–38.7] versus
40 ms [38–42.1], P=0.025; and 1061 ms [1051–1072] versus
1085 ms [1074–1095], P=0.001, respectively; Figure 2A). A
similar reduction was found at 30 days for T2* (36.3 ms [34.1–
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38.5] versus 41.1 ms [38.9–43.4], P=0.003), but this difference
was no longer significant for T1mapping (1075 ms [1065–1085]
versus 1079 ms [1069–1089], P=0.577; Figure 2B).
Secondary End Points
1. Relationship between CMR changes in T2* and T1
mapping with concomitant changes in:
a. LVEF: LVEF did not significantly differ between both
treatments at 7 or 30-day (Table 2). In the FCM-arm, a
decrease in T2* was significantly associated with an increase
in LVEF (Figure 3A-left). For T1-mapping, the direction of the
association was similar and significant (Figure 3A-right).
b. Quality of life: At 30 days, higher values of KCCQ were
observed in the FCM-arm (76.9 [73.6–80.1] versus 70
[66.8–73.3], P<0.001). However, there were no significant
differences across treatment arms at 7-day (Table 2).
Furthermore, we found a significant association between
the decrease in T1-mapping with the increase in KCCQ in the
FCM-arm (Figure 3B-right). The association between T2*
changes was not significant (Figure 3B-left).
c. Functional capacity:We failed to find significant differences
in 6MWT across both treatment strategies at both time points
(Table 2). However, we find a significant association between
reduction in T2* and increase in 6MWT in the active arm
(Figure 3C-left). For DT1-mapping, the association with
D6MWT was not significant (Figure 3C-right).
d. NYHA class: we found a significant lower value at 30 days
in patients allocated to FCM (1.72 [1.60–1.85] versus 1.90
[1.80–2.00], P<0.001). However, at 7-day, the differences
were not significant (Table 2). In the FCM-arm, the greater
improvement in NYHA class matched the reduction in T1-
mapping (Figure 3D-right). However, this correlation was not
significant for T2* (Figure 3D-left).
e. Natriuretic peptides: NT-proBNP did not differ across
treatment strategies at 7 or 30 days (Table 2). In the
active arm, we found an inverse association between CMR
changes and changes in NT-proBNP (Figure 3E).
2. Relationship between CMR changes (T2* and T1 mapping)
and changes in iron biomarkers. Least-square means
values of ferritin and TSAT values were significantly higher
in the FCM-arm at 7 and 30 days as compared with
placebo (Table 2). Furthermore, in the FCM arm, there was
an inverse association between DT2* (and DT1-mapping)
with D of surrogates of systemic iron repletion (Figure 4).
Discussion
For the first time in a clinical setting, we found that treatment
with FCM resulted in significant and short-term changes in
Figure 1. Flow chart. FCM indicates ferric carboxymaltose; NT-proBNP, N-terminal pro-B-type natriuretic
peptide.
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Table 1. Baseline Characteristics
Variables Placebo (n=26) Intravenous Iron (n=27) P Value
Demographics and medical history
Age, y 71 (67, 79) 73.5 (64, 77) 0.957
Male, n (%) 19 (73.1) 21 (77.8) 0.691
Hypertension, n (%) 19 (73.1) 22 (81.5) 0.465
Dyslipidemia, n (%) 16 (61.5) 18 (66.7) 0.697
Diabetes mellitus, n (%) 14 (53.8) 15 (55.6) 0.901
Former smoker, n (%) 16 (61.5) 15 (55.6) 0.659
Coronary artery disease, n (%) 10 (38.5) 13 (48.1) 0.477
Prior admission for AHF in the last year, n (%) 16 (61.5) 16 (59.3) 0.865
COPD, n (%) 6 (23.1) 7 (25.9) 0.810
CKD, n (%) 7 (26.9) 8 (29.6) 0.827
Stroke, n (%) 6 (23.1) 2 (7.4) 0.111
Peripheral artery disease, n (%) 4 (15.4) 4 (14.8) 0.954
NYHA functional class, n (%) 0.080
II 26 (100) 24 (88.9)
III 0 3 (11.1)
Vital signs
Heart rate, bpm 68 (64, 77) 73 (68, 82) 0.262
SBP, mm Hg 125 (113, 146) 117 (109, 132) 0.142
ECG
Atrial fibrillation, n (%) 14 (53.8) 10 (37.0) 0.219
LBBB, n (%) 6 (23.1) 6 (22.2) 0.941
LVEF, % 37 (32, 43) 40 (33.5, 45) 0.643
CMR parameters
LVEDVI, mL/m2 122.1 (101.5, 137.9) 107 (80.1, 143.9) 0.109
LVESVI, mL/m2 72.5 (55.1, 87.6) 63.5 (40.6, 84) 0.096
LVEDDI, mm/m2 30.8 (28, 33.5) 30.9 (26.9, 31.9) 0.493
LVESDI, mm/m2 23.1 (21.1, 26.9) 23.7 (23.0, 26.8) 0.648
LVEF, % 37 (31, 45) 43 (36, 48) 0.128
T2*, ms 37 (31, 42) 40 (34, 45) 0.196
T1-mapping, ms 1072 (1030, 1116) 1082 (1052, 1122) 0.173
Laboratory
Hemoglobin, g/dL 13.4 (12.7, 14.6) 13.1 (11.9, 13.4) 0.084
Anemia (WHO), n (%) 6 (23.1) 10 (37.0) 0.268
TSAT, % 15.4 (9.6, 20.0) 15.7 (12.0, 19.2) 0.790
Ferritin, ng/mL 47.8 (23.0, 114.0) 73.0 (56.0, 126.0) 0.072
Absolute iron deficiency, n (%) 19 (73.1) 18 (66.7) 0.611
Sodium, mEq/L 141 (140, 142) 140 (140, 142) 0.669
Potassium, mEq/L 4.6 (4.4, 4.8) 4.7 (4.2, 5.0) 0.852
Urea, mEq/L 59 (45, 84) 59 (45, 77) 0.669
Serum creatinine, mg/dL 1.1 (0.9, 1.5) 1.1 (0.9, 1.4) 0.783
Continued
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CMR sequences that are consistent with myocardial iron
repletion. Interestingly, these surrogates of myocardial
iron repletion were, in most cases, related to systemic iron
repletion and short-term improvement in LVEF and other
surrogates of severity such as 6MWT and quality of life. Our
results are in line with prior studies showing the clinical utility
of iron supplementation in HF-ID patients, and more impor-
tantly, provide new insights into the role that myocardial iron
repletion may play in these beneficial effects.
ID and Heart Failure
Iron is a micronutrient that plays a crucial role in oxygen
transport and storage, and as a component of the mitochon-
drial respiratory chain is involved in energy production.10–
13,23 In vitro studies have shown that cellular iron depletion
in cardiomyocytes is associated with mitochondrial dysfunc-
tion, impaired ATP synthesis, increased oxidative stress in
these cells, and that all these factors promote a profound
impairment of systolic and diastolic properties of the
cardiomyocytes.12 In the clinical context, ID is highly
prevalent in patients with HF and commonly associated with
adverse outcomes.1–4 In these patients, treatment of ID with
FCM improves symptoms, exercise capacity, and quality of
life, and reduces the risk of readmission.1,5–8 However, the
pathophysiological link between exogenous iron repletion and
clinical improvement is not totally elucidated. A subanalysis
of the FAIR-HF (Ferrinject assessment in patients with iron
deficiency and chronic heart failure) study and other studies
showed that clinical improvement in response to intravenous
iron administration occurs in patients with or without anemia,
suggesting that the beneficial effect of iron administration is,
at least in part, independent of the erythropoietic response.24
Iron Supplementation and Myocardial
Performance in HF Patients
In the clinical setting, the evidence regarding the myocardial
effect of iron supplementation is scarce. For example, in a
small randomized trial with HF, ID, and chronic kidney
disease, Toblli et al25 showed that iron sucrose administration
translated into a significant 6-month improvement in LVEF
estimated by echocardiography (6.6 3.8%). Other studies
have also shown a significant reduction in the plasma level of
NT-proBNP and attenuation of hypertrophic cardiac remodel-
ing.26,27 The present study goes a step further in this regard
and provides evidence that the improvement is related to
benefits at the cardiac level with myocardial iron repletion
that translates in improvements in cardiac function and
patient functioning.
Quantification of Myocardial Iron Changes by
CMR
CMR is an accurate and noninvasive technique that enables
the characterization of cardiac structure, function, and risk
Table 1. Continued
Variables Placebo (n=26) Intravenous Iron (n=27) P Value
eGFR, mL/min per 1.73 m2 64.1 (48.9, 79.3) 59.4 (50.0, 71.3) 0.854
NT-proBNP, pg/mL 1213 (1010, 2667) 1990 (976, 2830) 0.505
Medical treatment
Diuretics, n (%) 24 (92.3) 25 (92.6) 0.969
b-blockers, n (%) 21 (80.8) 25 (92.6) 0.204
ACEI, n (%) 6 (23.1) 7 (25.9) 0.810
ARB, n (%) 4 (15.4) 5 (18.5) 0.761
Sacubitril/valsartan, n (%) 8 (30.8) 10 (37.0) 0.630
Spironolactone, n (%) 3 (11.5) 2 (7.4) 0.607
Eplerenone, n (%) 13 (50.0) 10 (37.0) 0.341
Digoxin, n (%) 4 (15.4) 1 (3.7) 0.146
Ibavradine, n (%) 1 (3.9) 4 (14.8) 0.172
Nitrates, n (%) 2 (7.7) 2 (7.4) 0.969
WHO criteria for anemia: adult male, hemoglobin 13 g/dL; adult, nonpregnant female, hemoglobin 12 g/dL; adult pregnant female, hemoglobin 11 g/dL. Absolute iron deficiency: ferritin
<100 ng/mL. Values expressed asmedian (interquartile range); categorical variables are presented as percentages. ACEI indicates angiotensin-converting enzyme inhibitors; AHF, acute heart
failure; ARB, angiotensin II receptor blockers; bpm, beats per minute; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; COPD, chronic pulmonary obstructive disease; eGFR,
estimated glomerular filtration rate; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVEDDI, left ventricle end-diastolic diameter index; LVEDVI, left ventricle end-diastolic
volume index; LVESDI, left ventricle end-systolic diameter index; LVESVI, left ventricle end-systolic volume index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart
Association; SBP, systolic blood pressure; TSAT, transferrin saturation; WHO, World Heart Organization.
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stratification.28 This technique has been used to estimate
myocardial iron content.15,16 For example, lower T2* CMR
sequence values have been shown to provide a reliable
assessment of myocardial iron overload.15,16 More interest-
ingly, changes in T2* following chelation therapy are
strongly related to the response to therapy in patients
Figure 2. T2* and T1 mapping after administration of FCM. A, Seven-day comparison of LSM (95% CIs) between FCM and placebo. B, Thirty-
day comparison of LSM (95% CIs) between FCM and placebo. FCM indicates ferric carboxymaltose; LSM, least-square means from a linear mixed
regression analysis.
Table 2. Effect of Intervention on Surrogates of Severity and Iron Status Markers
Variables Placebo (n=26) Intravenous Iron (n=27) P Value
7-d
LVEF, % 42.6 (40.3–45) 42.5 (40.2–44.8) 0.916
KCCQ 72.2 (66.8–77.6) 77.5 (72.5–82.5) 0.203
6MWT, m 287 (269–304) 297 (280–313) 0.402
NYHA class 1.91 (1.82–2.00) 1.90 (1.84–1.96) 0.700
NT-proBNP, pg/mL 1870 (1609–2131) 2305 (1859–2751) 0.102
Ferritin, ng/mL 102 (71–132) 993 (908–1078) <0.001
TSAT, % 16.1 (14.1–18.1) 41.3 (34.5–48.1) <0.001
30-d
LVEF, % 40.9 (38.2–43.7) 44.8 (42.1–47.6) 0.056
KCCQ 70 (66.8–73.3) 76.9 (73.6–80.1) <0.001
6MWT, m 299 (266–332) 299 (279–320) 0.992
NYHA class 1.90 (1.80–2.00) 1.72 (1.60–1.85) <0.001
NT-proBNP, pg/mL 2656 (1891–3421) 2366 (1741–2992) 0.675
Ferritin, ng/mL 96 (68–124) 456 (434–479) <0.001
TSAT, % 15 (14.1–15.8) 30.4 (26.1–34.8) <0.001
Values presented are the least-squaremeans (95%CIs) from eachmixed linear regressionmodel. All models were adjusted by hospital center (as a cluster variable), the interaction term Tx9visit
(7 and 30-day), baseline value of hemoglobin, and the baseline (pretreatment) value of the regressed outcome. 6MWT indicates distance walked in 6 minutes; KCCQ, Kansas City
Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TSAT, transferrin saturation.
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Figure 3. Association of posttreatment changes in myocardial iron content (T2* and T1 mapping) with concomitant changes in
surrogate markers of disease severity in the active-arm. A, Changes in CMR sequences and changes in LVEF; B, Changes in CMR
sequences and changes in KCCQ; C, Changes in CMR sequences and changes in 6MWT; D, Changes in CMR sequences and changes
in NYHA class; E, Changes in CMR sequences and changes in NT-proBNP. Values are the least-square means (95% CIs) from each
linear regression analysis (OLS). 6MWT indicates distance walked in 6 minutes; CMR, cardiac magnetic resonance; KCCQ, Kansas City
Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA,
New York Heart Association.
Figure 4. Association of posttreatment changes in myocardial iron content (T2* and T1 mapping) with concomitant changes in systemic
iron status in the active arm. A, Changes in CMR sequences and changes in ferritin; B, A, Changes in CMR sequences and changes in TSAT.
Values are the least-square means (95% CIs) from each linear regression analysis (OLS). TSAT indicates transferrin saturation.
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with iron overload.29 Regarding ID, in a small case–control
study, Nagao et al17 suggested that cardiac T2* may also
play a role in the quantification of myocardial ID in
nonischemic HF. In addition, these authors reported that
T2* CMR was related to an increased risk of adverse
outcomes.17 Furthermore, new CMR techniques, such as T1
mapping, have been found to be a potential alternative tool
for myocardial iron quantification.18 To the best of our
knowledge, this is the first controlled clinical trial showing
that treatment with FCM is associated with significant
short-term decreases in T1 mapping and T2* CMR values,
changes that are indicative of myocardial iron repletion.
Indeed, we found a 7-day decrease in both CMR sequences;
however, at 30 days only T2* was decreased. Interestingly,
these changes were strongly related to a concomitant
improvement in LVEF and other surrogates of disease
severity. Unfortunately, our study was not designed to
further evaluate this discrepancy among T2* and T1
mapping at 30 days. Beyond the potential role of type II
error, we speculate that changes in T1 mapping at later
times may also reflect changes in other tissue character-
istics. T1-mapping values are influenced by several other
conditions, such as fibrosis, inflammation/edema, amyloid,
and Fabry disease.18 Despite the fact that all enrolled
patients exhibited systemic ID, baseline T2* values did not
correlate with systemic markers of ID. This fact may reflect
a lack of agreement between traditional markers of ID and
myocardial tissue iron, as shown in previous publications30
or, perhaps, a lack of specificity of the baseline values of
these CMR sequences for identifying myocardial ID in
clinical practice. We do not believe the present findings
have a direct translation into daily clinical practice.
However, given the emerging role of iron biology in the
pathophysiology of HF, we believe further research should
test a clinical utility of the present findings or focus on the
development of more specific and accurate noninvasive
imaging techniques and better biomarkers for estimating
myocardial iron content. This would translate into a better
selection of HF patients who would most benefit from iron
supplementation.
Limitations
This trial has some limitations to be acknowledged. First,
some negative results may be explained by insufficient
statistical power. Second, CMR end points are well-estab-
lished imaging sequences for evaluating myocardial iron
overload but not myocardial iron deficiency. In addition, their
values and changes are not specific to myocardial iron
content and may reflect the turnover of other tissue. Neither
CMR sequence can discriminate whether tissue changes
occur in an intra- or extracellular compartment. Third, as
limited by the study design, we cannot prove any correlation
between myocardial histological or myocardial energetic
efficiency aspects with the administration of FCM. Performing
a myocardial biopsy to conduct such studies would be
considered ethically conflicting. Fourth, in the present study
we did not evaluate the effect of iron treatment on skeletal
muscle function, a potential mechanism that may also
explain the beneficial effect of iron in HF patients. Fifth, in
order to avoid interference with CMR sequences, patients
with cardiac devices were excluded from this study. Sixth,
the subgroup analysis was not reported given the small
size of the study. Finally, despite the fact that the
magnitude of changes we found in surrogates of the
disease (LVEF, quality of life, functional capacity, and
NYHA class) appears not to be clinically relevant, this
study was not designed to quantify the effect of FCM nor
magnitude of these changes.
Conclusions
In patients with stable HF and ID, administration of FCM led
to a greater reduction in CMR T2* and T1-mapping values
compared with placebo in the short-term. Both changes are
suggestive of myocardial iron repletion. Further studies are
warranted to confirm these findings and to evaluate the
potential utility of CMR for assessing myocardial iron
content.
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Table S1. Inclusion and exclusion criteria. 
Inclusion criteria 
▪ Outpatients with chronic HF  
▪ Oder than 18 years 
▪ NYHA II-III with optimal medical treatment in the last 4 weeks, without dose 
changes of HF treatment in the last 2 weeks (except for diuretics) 
▪ NT-proBNP >400 pg/mL 
▪ LVEF <50% in the last 12 months 
▪ ID, defined as: serum ferritin <100μg/L, or 100-299μg/L if TSAT <20% and 
Hemoglobin <15 g/dL 
▪ Participants are willing and able to give informed consent for participation in the 
study 
Exclusion criteria 
▪ Known intolerance to FCM 
▪ History of acquired iron overload 
▪ Severe valve disease or cardiac surgery scheduled in the next 30 days 
▪ ACS, TIA, or ictus in the 3 previous months 
▪ CABG, major surgery, or cardiac, cerebrovascular or aortic percutaneous 
intervention (diagnostic angiography is allowed) in the 3 previous months 
▪ Scheduled revascularization in the next 30 days 
▪ Scheduled CRTD implantation in the next 30 days 
▪ Active bleeding in the last 30 days 
▪ Active infection or malignancy 
▪ Immediate need for transfusion or hemoglobin ≥15g/dL 
▪ Anemia for reasons other than ID 
▪ Immunosuppressive therapy or dialysis 
▪ History of treatment with erythropoietin, intravenous iron, or transfusion in the 
previous 12 weeks 
▪ Treatment with oral iron at doses >100mg/day in the previous week  
▪ Contraindications to MRI, including non-compatible pacemakers or defibrillators, 
cochlear implants, cerebral aneurysm clips, claustrophobia, or abdominal obesity 
not allowing the realization of the test due to a physical space problem. 
▪ Pregnant or lactating women 
▪ Subject of childbearing age who is unwilling to use adequate contraceptive 
measures during the study and up to 5 half-lives after the administration of study 
treatment 
▪ Participation in another trial at the time of inclusion or in the previous 30 days  
▪ Any disorder that compromises the ability to sign informed consent and/or comply 
with study procedures 
 
ACS: acute coronary syndrome; CABG: coronary artery by-pass surgery,CRTD: 
cardiac resynchronization therapy device; HF: heart failure; NT-proBNP: amino-
terminal pro-brain natriuretic peptide; FCM: ferric carboxymaltose, ID: iron deficiency; 
LVEF: left ventricle ejection fraction; NYHA: New York Heart Association; TIA: 
transient ischemic attack, TSAT: transferrin saturation.  






































CMR T2*, msec 37 (31, 42) 40 (34, 45) 0.217 39 (35, 42) 38 (35, 41) 0.644 38.5 (34, 45) 38 (36, 42) 0.769 0.001 
CMR LVEF, % 36 (31, 45) 44 (36, 49) 0.242 39 (34, 49) 43 (35, 53) 0.365 40 (31, 46) 45 (38, 53) 0.129 0.017 









































Ferritin, pg/mL 47.8 (23.0, 73.0 (56.0, 0.217 45.5 (21.0, 944.0 (790.8, <0.001 55.5 (29.3, 447.0 (294.0, <0.001 <0.001 
































CMR: cardiac magnetic resonance; KCCQ: Kansas City Cardiomyopathy Questionnaire; LVEF: left ventricle ejection fraction; NT-proBNP: 
amino-terminal pro-brain natriuretic peptide; TSAT: transferrin saturation; 6MWT: 6-minute walking test. 
Continuous values are expressed as median (interquartile range). 
 
